Polpharma Biologics has secured US and European review for intravenous biosimilar vedolizumab PB016, matching Alvotech’s regulatory reach but trailing its broader strategy, which also includes subcutaneous formulations.
Polpharma Biologics has secured US and European review for intravenous biosimilar vedolizumab PB016, matching Alvotech’s regulatory reach but trailing its broader strategy, which also includes subcutaneous formulations.